Shuttle Pharmaceuticals Holdings, Inc., in conjunction with its subsidiary Shuttle Pharmaceuticals, Inc., is committed to the identification, advancement, and commercialization of pharmaceutical agents crafted to heighten the susceptibility of cancerous cells to radiation therapy. Its current portfolio of clinical-phase treatments features Ropidoxuridine, an orally administered halogenated pyrimidine, which is intended for individuals afflicted with brain tumors and soft tissue sarcomas. Additionally, the company is progressing Doranidazole, an injectable compound designed to make oxygen-deprived tumor cells more responsive to radiation, targeting malignancies of the pancreas, lungs, and liver. This enterprise was established in 2012 and maintains its principal operations in Rockville, Maryland.
United Dogecoin Purchases Dogecoin Miners and Secures Renewable Energy Data Centre Site
United Dogecoin, a subsidiary of Shuttle Pharmaceutical Holdings, purchased its first fleet of ElphaPex DG1+ mining units and secured a renewable energy data center site.
The miners deliver 14.4 GH/s per unit and are expected to be operational within approximately 60 days, leveraging hydroelectric energy at a cost of US$0.064 per kilowatt hour.
Management stated the company is ramping up operations on its path to becoming the largest Dogecoin miner by hashrate.